{
    "organizations": [],
    "uuid": "dac81af97a56dcae4bcdf67ba5c79a5900e9ef2f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/recro-pharma-fda/fda-declines-to-approve-recro-pharmas-non-opioid-pain-shot-idUSL3N1SV4I4",
    "ord_in_thread": 0,
    "title": "FDA declines to approve Recro Pharma's non-opioid pain shot",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "The U.S. Food and Drug Administration on Thursday declined to approve Recro Pharma’s IV meloxicam noting the pain-relieving effect of the drug did not meet its expectations.\nThe drug is a non-opioid injection to treat moderate-to-severe pain.\nUnlike the drug’s oral version, which has been on the market for several years, Recro’s intravenous formulation is long-acting for treating acute pain, particularly in patients who have undergone surgery. (Reporting by Sharnya G and Tamara Mathias; Editing by Shailesh Kuber)\n ",
    "published": "2018-05-24T19:08:00.000+03:00",
    "crawled": "2018-05-25T16:06:16.001+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "food",
        "drug",
        "administration",
        "thursday",
        "declined",
        "approve",
        "recro",
        "pharma",
        "iv",
        "meloxicam",
        "noting",
        "effect",
        "drug",
        "meet",
        "expectation",
        "drug",
        "injection",
        "treat",
        "pain",
        "unlike",
        "drug",
        "oral",
        "version",
        "market",
        "several",
        "year",
        "recro",
        "intravenous",
        "formulation",
        "treating",
        "acute",
        "pain",
        "particularly",
        "patient",
        "undergone",
        "surgery",
        "reporting",
        "sharnya",
        "g",
        "tamara",
        "mathias",
        "editing",
        "shailesh",
        "kuber"
    ]
}